Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

Seminars in Oncology

Volumn 29, Issue 5 SUPPL. 14, 2002, Pages 3-9

  Arteaga, Carlos L ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKING AGENT; ERLOTINIB; GEFITINIB; HUMAN MONOCLONAL ANTIBODY 225; LAPATINIB; MONOCLONAL ANTIBODY 528; MURINE MONOCLONAL ANTIBODY 225; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL TRANSFORMATION; CLINICAL TRIAL; CONFERENCE PAPER; CROSS REACTION; DRUG RECEPTOR BINDING; DRUG TARGETING; EPITHELIUM CELL; GASTROINTESTINAL SYMPTOM; GENE OVEREXPRESSION; HUMAN; IC 50; NEOPLASM; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0037010076     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70085-7     Document Type: Conference Paper

References (59)

1. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000
2. Yarden Y, Sliwkowski MX: Untangling the erbB signalling network. Nature Rev Mol Cell Biol 2:127-137, 2001
3. Hackell PO, Zwick E, Prenzel N, et al: Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184-189, 1999
4. Moniola AO, Neve RM, Lane HA, et al: The erbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000
5. Downward J, Yarden Y, Mayes E, et al: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527, 1984
6. Sandgreen EP, Luetteke NC, Palmitter RD, et al: Over-expression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121-1135, 1990
7. Matsui Y, Halter S, Holt J, et al: Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61:1147-1155, 1990
8. Kokai Y, Myers JN, Wada T, et al: Synergistic interaction of p185c-neu and the EGF receptor leads to transformation cransformacion of rodent fibroblasts. Cell 58:287-292, 1987
9. Muller WJ, Arteaga CL, Muthuswammy SK, et al: Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16:5726-5736, 1996
10. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
11. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53:2379-2385, 1993
12. Klijn JG, Berns PM, Schmitz PI, et al: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3-17, 1992
13. Grandis JR, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
14. Yonemura Y, Takamura H, Ninomiya I, et al: Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology 49:157-161, 1992
15. Hirai T, Kuwahara M, Yoshida K, et al: Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis Esophagus 11:221-225, 1998
16. Tateishi M, Ishida T, Mitsudomi T, et al: Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50:7077-7080, 1990
17. Yamanaka Y, Fries H, Kobrin MS, et al: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565-569, 1993
18. Ekstrand AJ, James CD, Cavanee WK, et al: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172, 1991
19. Fontanini G, De Laurentiis M, Vignati S, et al: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241-249, 1998
20. Tateishi M, Ishida T, Kohdono S, et al: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 3:109-113, 1994
21. Xia W, Lau YK, Zhang HZ, et al: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5:4164-4174, 1999
22. Harris AL, Nicholson S, Sainsbury JR, et al: Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones, and interactions with neu. J Steroid Biochem 34:123-131, 1989
23. Scher HI, Sarkis A, Reuter V, et al: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor-alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550, 1995
24. Klijn JG, Look MP, Portengen H, et al: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study. Breast Cancer Res Treat 29:73-83, 1994
25. Veale D, Kerr N, Gibson GJ, et al: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162-165, 1993
26. Bartlett JM, Langdon SP, Simpson BJ, et al: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73:301-306, 1996
27. Turkeri LN, Erton ML, Cevik I, et al: Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 51:645-649, 1998
28. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
29. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001
30. Redemann N, Holzmann B, von Ruden T, et al: Anti-oncogenic activity of signaling-defective epidermal growth factor receptor mutants. Mol Cell Biol 12:491-498, 1992
31. Fan Z, Masui H, Atlas I, et al: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth, factor receptor monoclonal antibodies. Cancer Res 53:4322-4328, 1993
32. Fan Z, Lu Y, Wu X, et al: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269:27595-27602, 1994
33. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318, 1995
34. Gill GN, Kawamoto T, Cochet C, et al: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259:7755-7760, 1983
35. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
36. Wu X, Fan Z, Masui H, et al: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905, 1995
37. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res 59:1935-1940, 1999
38. Rodeck U, Herlyn M, Herlyn D, et al: Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunologically mediated and effector cell-independent effects. Cancer Res 47:3692-3696, 1987
39. Sampson JH, Crotty LE, Lee S, et al: Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 97:7503-7508, 2000
40. Modjtahedi H, Eccles S, Sandle J, et al: Differentiation or immune destruction: Two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res 54:1695-1701, 1994
41. Naramura M, Gillies SD, Mendelsohn J, et al: Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37:343-349, 1993
42. Divgi CR, Welt S, Kris M, et al: Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous lung carcinoma. J Natl Cancer Inst 83:97-104, 1991
43. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 7)
44. Klapper LN, Waterman H, Sela M, et al: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384-3388, 2000
45. Al-Abeidi F, Lam KS: Development of inhibitors for protein tyrosine kinases. Oncogene 19:5690-5701, 2000
46. Baselga J, Averbuch SD: ZD1839 ('Iressa') as an anti-cancer agent. Drugs 60: 33-40, 2000 (suppl 1)
47. Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124, 2002
48. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
49. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
50. Smaill JB, Rewcastle GW, Loo JA, et al: Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido(3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem 43:1380-1397, 2000
51. Sherwood V, Bridges AJ, Denny WA, et al: Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD158780 and a new irreversible inhibitor PD183805. Proc Am Assoc Cancer Res 40:723, 1999 (abstr)
52. Torance CJ, Jackson PE, Montgomery E, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024-1028, 2000
53. Bruns CJ, Solorzano CC, Harbison MT, et al: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935, 2000
54. Xia W, Mullin R, Keith B, et al: GW2016, a dual inhibitor of erbB-2 and EGFR tyrosine kinases: Effects on receptor tyrosine autophosphorylation, downstream signaling intermediaries and in vivo anti-tumor activity. Proc Am Assoc Cancer Res 42:3635, 2001 (abstr)
55. Fry DW: Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des 15:3-16, 2000
56. Sauter G, Maeda T, Waldman FM, et al: Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 148:1047-1053, 1996
57. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
58. Moscatello DK, Holgado-Madruga M, Godwin AK, et al: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539, 1995
59. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000